A Systematic Review of Efficacy and Safety of Plasma-Derived von Willebrand Factor/Factor VIII Concentrate (Voncento) in von Willebrand Disease

被引:0
|
作者
Rugeri, Lucia [1 ]
Thomas, Will
Schirner, Kathrin
Heyder, Lisa
Auerswald, Guenter
机构
[1] Hop Cardiol, Unite Hemostase Clin, Hosp Civils Lyon, Lyon, France
关键词
blood products; factor VIII; systematic review; von Willebrand disease; von Willebrand factor; WFH; 2021; GUIDELINES; INHIBITOR DEVELOPMENT; VENOUS THROMBOSIS; CLINICAL-EFFICACY; MANAGEMENT; BIOSTATE(R); DIAGNOSIS; PHARMACOKINETICS; POPULATION; PREVENTION;
D O I
10.1055/a-2253-9701
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background For the treatment of von Willebrand disease (VWD), von Willebrand factor (VWF) concentrates can be used in on-demand, long-term prophylaxis, and surgical prophylaxis regimens. Methods This systematic literature review was conducted to evaluate the efficacy, consumption, and safety of plasma-derived human coagulation FVIII/human VWF (pdVWF/FVIII; Voncento/Biostate) for the treatment of patients with any inherited VWD type. An electronic search was conducted in MEDLINE and Cochrane Library databases on VWD therapies. All retrieved publications were assessed against predefined inclusion/exclusion criteria following the Cochrane group recommendations. Associated pharmacovigilance data were collected across the same time period. Results Eleven publications from eight study cohorts were identified for data retrieval. All were from multicenter studies and included both pediatric and adult patients. Eight publications included evaluations of the efficacy of pdVWF/FVIII for on-demand treatment, eight included long-term prophylactic treatment, and eight included surgical prophylaxis. Treatment protocols and VWF administration methods differed between studies, as did safety evaluations. The clinical response was rated as excellent/good for on-demand treatment in 66 to 100% of nonsurgical bleeds, 89 to 100% in the treatment of breakthrough bleeds during long-term prophylaxis treatment, and hemostatic efficacy in surgical procedures was 75 to 100%. Pharmacovigilance data confirmed a low incidence of adverse events in treated patients. Conclusion This review provides a comprehensive summary of studies that evaluated the use of pdVWF/FVIII in VWD demonstrating the long-term effectiveness and safety of this pdVWF/FVIII across all ages, types of VWD, and treatment settings.
引用
收藏
页码:828 / 841
页数:14
相关论文
共 50 条
  • [21] Clinical Efficacy and Safety of Fanhdi((R)), a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study
    Jimenez-Yuste, Victor
    Alvarez-Roman, Maria Teresa
    Palomo Bravo, Angeles
    Galmes, Bernardo J.
    Nieto Hernandez, Maria del Mar
    Benitez Hidalgo, Olga
    Marzo Alonso, Cristina
    Perez Gonzalez, Noelia Florencia
    Coll, Julia
    Nunez, Ramiro
    Carrasco, Marina
    Garcia Candel, Faustino
    Gonzalez-Porras, Jose Ramon
    Hernandez Garcia, Carmen
    Varo Castro, Maria Jose
    Mir, Roser
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [22] Clinical Efficacy and Safety of Fanhdi (R), a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study
    Jimenez-Yuste, Victor
    Alvarez-Roman, Maria Teresa
    Bravo, Angeles Palomo
    Galmes, Bernardo J.
    Hernandez, Maria del Mar Nieto
    Hidalgo, Olga Benitez
    Alonso, Cristina Marzo
    Gonzalez, Noelia Florencia Perez
    Coll, Julia
    Nunez, Ramiro
    Carrasco, Marina
    Candel, Faustino Garcia
    Gonzalez-Porras, Jose Ramon
    Garcia, Carmen Hernandez
    Castro, Maria Jose Varo
    Mir, Roser
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [23] A RETROSPECTIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF A PLASMA-DERIVED VON WILLEBRAND FACTOR-CONTAINING FVIII CONCENTRATE, IN PATIENTS WITH VON WILLEBRAND DISEASE IN ITALY (RECLASFAWILL)
    Federici, A. B.
    Mir, R.
    HAEMOPHILIA, 2023, 29 : 55 - 56
  • [24] Treatment and prevention of acute bleedings in von Willebrand disease - efficacy and safety of Wilate®, a new generation von Willebrand factor/factor VIII concentrate
    Berntorp, E.
    Windyga, J.
    HAEMOPHILIA, 2009, 15 (01) : 122 - 130
  • [25] von Willebrand factor/factor VIII concentrate (Wilate) prophylaxis in children and adults with von Willebrand disease
    Sidonio Jr, Robert F.
    Boban, Ana
    Dubey, Leonid
    Inati, Adlette
    Kiss, Csongor
    Boda, Zoltan
    Lissitchkov, Toshko
    Nemes, Laszlo
    Novik, Dzmitry
    Peteva, Elina
    Taher, Ali T.
    Timofeeva, Margarita Arkadevna
    Vilchevska, Kateryna V.
    Vdovin, Vladimir
    Werner, Sylvia
    Knaub, Sigurd
    Khayat, Claudia Djambas
    BLOOD ADVANCES, 2024, 8 (06) : 1405 - 1414
  • [26] Continuous infusion of human plasma-derived von Willebrand factor concentrate as an effective therapy in a patient with acquired von Willebrand disease
    Patel, S. B.
    Rodgers, G. M.
    HAEMOPHILIA, 2014, 20 (06) : E411 - E414
  • [27] Plasma-derived, purified, pasteurised von Willebrand factor/factor VIII concentrate in the treatment of patients with von Willebrand disease and haemophilia a: update of a long-term observational study
    Wermes, C.
    Holzhauer, S.
    Halimeh, S.
    Kemkes-Matthes, B.
    Sommerer, P.
    Wieland, I
    Krause, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 497 - 497
  • [28] Recombinant vs plasma-derived von Willebrand factor to prevent postpartum hemorrhage in von Willebrand disease
    Machin, Nicoletta
    Ragni, Margaret V.
    BLOOD ADVANCES, 2020, 4 (14) : 3234 - 3238
  • [29] Safety and efficacy of continuous infusion of a combined factor VIII -: von Willebrand factor (vWF) concentrate (Haemate-P™) in patients with von Willebrand disease
    Lubetsky, A
    Schulman, S
    Varon, D
    Martinowitz, U
    Kenet, G
    Gitel, S
    Inbal, A
    THROMBOSIS AND HAEMOSTASIS, 1999, 81 (02) : 229 - 233
  • [30] Individually tailored prophylaxis in Type 3 von Willebrand Disease patients: efficacy and safety of a von Willebrand Factor concentrate with a low factor VIII content
    Gouider, E.
    Peerlinck, K.
    Hermans, C.
    Gadisseur, A.
    Klukowska, A.
    Knuchel, N.
    Stevens, W.
    Matysiak, M.
    Meddeb, B.
    Henriet, C.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 945 - 945